Form 4: Travere Therapeutics Director Timothy Coughlin Reports Acquisition and Disposal of Shares

Director Timothy Coughlin reports acquisition of 6,500 shares and disposal of shares of Travere Therapeutics, Inc. on May 15, 2025.

Summary

• On May 15, 2025, Timothy Coughlin, a director of Travere Therapeutics, Inc., acquired 6,500 shares of common stock.
• These shares were acquired automatically under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
• The director also disposed of 55,500 shares.
• Coughlin also acquired options to buy 19,500 shares of common stock at an exercise price of $21.15, vesting over one year and expiring on May 15, 2035.
• Following these transactions, Coughlin directly owns 19,500 derivative securities.

Sentiment

Score: 5

Explanation: The document itself is neutral as it simply reports transactions. The acquisition of shares and options could be seen as mildly positive, while the disposal of shares could be seen as mildly negative. Overall, it's a routine filing with no strong positive or negative implications.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Negatives

• The disposal of 55,500 shares by the director could be interpreted negatively by some investors.

Risks

• The vesting schedule of the stock options means the director's incentives are aligned with the company's performance over the next year.
• Market conditions and company performance could impact the value of the acquired shares and options.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the equity award suggests a one-year horizon for performance alignment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's views on the company's prospects.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a common practice in the pharmaceutical industry.
• The vesting schedule and exercise price of the options are typical for such grants.
• Comparable companies like BioMarin Pharmaceutical and Sarepta Therapeutics also utilize equity incentive plans for their directors.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment.
• The equity grant aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Travere Therapeutics, Director, Equity Incentive Plan, Stock Options, Share Acquisition, Share Disposal, Beneficial Ownership, Form 4, TVTX